Clinical Scorecard: Exploring the Influence of Genetic Vulnerability to Neurodevelopmental Disorders on Antipsychotic Efficacy in Schizophrenia: Insights from a Postmortem Brain Analysis

At a Glance

Key Highlights

• Antipsychotic responsiveness score for positive symptoms negatively correlates with ADHD-PRS and positively with ASD-PRS, though not statistically significant after correction.
• Gene expression differences in prefrontal cortex linked to ADHD genetic risk involve neuropsychiatric disorder-related genes and pathways related to neuronal systems and mitochondrial function.
• Genetic overlap between schizophrenia and neurodevelopmental disorders may influence symptom severity and treatment response, highlighting the need for personalized approaches.

Guideline-Based Recommendations

Diagnosis

• Consider genetic risk profiling for ADHD and ASD in patients with schizophrenia to understand symptom heterogeneity.
• Use clinical scales such as PANSS and PAUSS to assess symptom severity and autistic traits in schizophrenia.

Management

• Monitor antipsychotic treatment responsiveness, especially in patients with high genetic risk for neurodevelopmental disorders.
• Recognize that approximately 30% of patients may exhibit treatment-resistant schizophrenia despite adequate antipsychotic therapy.

Monitoring & Follow-up

• Regularly assess symptom domains (positive, negative, general psychopathology) and antipsychotic responsiveness scores.
• Consider genetic and molecular markers as potential future tools for monitoring treatment response.

Risks

• Treatment resistance may be associated with higher genetic risk for ADHD and ASD.
• Symptom overlap with neurodevelopmental disorders may complicate clinical presentation and management.

Patient & Prescribing Data

Patients with schizophrenia exhibiting variable genetic risk for ADHD and ASD

Genetic vulnerability to neurodevelopmental disorders may modulate antipsychotic efficacy, particularly for positive symptoms, suggesting the potential for stratified treatment approaches.

Clinical Best Practices

• Incorporate genetic risk assessment for ADHD and ASD when evaluating schizophrenia patients to inform prognosis and treatment planning.
• Use comprehensive symptom rating scales including PANSS and PAUSS to capture neurodevelopmental traits.
• Recognize the heterogeneity of antipsychotic response and consider alternative strategies for treatment-resistant cases.
• Support further research with larger cohorts to validate genetic and molecular markers influencing treatment response.

References

• Tohoku Postmortem Brain Bank and DNA Bank for Psychiatric Research